Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

factman777 15 posts  |  Last Activity: May 20, 2016 10:49 AM Member since: Oct 10, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • "Weekly Biotech Round-Up (May 20, 2016):

    COMING UP

    Next week I hope to publish my CEO interview with Mark Perrin of NVIV. That should really be a good one."

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Jason Napodano's reply to my tweet about the Perrin interview...

    "Already did it, just waiting for them to review the transcript and get it back to me. Taking forever. Hopefully Monday or Tuesday."

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • From Jason Napodano's BioNap, Inc. dated today 5/6/2106:

    "Coming Up NEXT WEEK:
    Next week I have two CEO interviews planned. One with the Mark Perrin, CEO of InVivo Therapeutics (NASDAQ: NVIV) and another with Dror Ben-Asher, CEO of RedHill Biopharma (NASDAQ: RDHL). These are two of my favorite ideas right now and I'm really looking forward to sharing my conversation with both CEO's on my website next week.
    ________________________________________
    Thank you for reading my work. I'm happy to answer any questions!

    Jason Napodano, CFA"

    Just the Facts,
    FactMan777

    Sentiment: Strong Buy

  • From Mark Perrin:

    " We now only need one additional patient with an AIS conversion to meet the Objective Performance Criterion (OPC) "
    "We project our funds will last us through the end of 2017, by which time we expect to have filed a Humanitarian Device Exemption (HDE) application for approval of the Neuro-Spinal Scaffold™.”

    My understanding is that once the next patient converts they are going to approach the FDA for early approval. Remember they have built an excellent relationship with the FDA.

    Also, the company should soon initiate a study for cervical spinal cord injuries, If the NSS works in the mid to lower spine it certainly will work in the upper spine (cervical). And the benefits from the NSS implanted in the cervical region of the spine will be exponentially greater.

    Just my opinion,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    Patient #7 - 30 day eval

    by onemill2go Apr 29, 2016 9:56 AM
    factman777 factman777 Apr 29, 2016 11:10 AM Flag

    Patients are evaluated at 1, 2, 3, and 6 months.

    Patient #6 converted at the 2 month evaluation.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • factman777 by factman777 Apr 26, 2016 9:39 AM Flag

    "$NVIV OPC for INSPIRE trial was 25% of n=20 improve. That’s 5 patients. They are at 4 of 7 right now!! I think they file early."

    "This is great news for $NVIV. They are at 4 of 7 patients improved so far, with 1 patient will under review."

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    Patients

    by vincent_vivo Apr 8, 2016 11:12 AM
    factman777 factman777 Apr 8, 2016 1:20 PM Flag

    I believe that once we have 5 patients that convert on the AIS scale InVivo will approach the FDA and try to end the study early since they will already have reached the 5/20=25% requirement.

    Remember that InVivo has a great working relationship with the FDA and several times in the past they have reduced their timelines such as:

    - concurrent enrollment of patients 3-5
    - rolling the pilot study into the pivotal study where the 5 patients in the pilot are counted in the pivotal

    Just my opinion,
    -FactMan777

    Sentiment: Strong Buy

  • factman777 factman777 Mar 22, 2016 1:19 AM Flag

    From the press release:

    The offering is expected to close on or about March 18, 2016, subject to customary closing conditions.

    "on or about March 18, 2016"

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    $7.08 close. Good Buy point.

    by factman777 Mar 15, 2016 4:33 PM
    factman777 factman777 Mar 15, 2016 8:25 PM Flag

    Each unit consists of 1/2 warrant.

    3,733,333 unit plus 560,000 = 4,293,333 units

    4,293,333 / 2 = 2,146,667 warrants

    2,146,667 * $10,00 = $21,466,667

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • $7.08 is a discount of 5.6% off the offering price of $7.50 a share.

    Not concerned with the warrants because:

    - the stock has to be above $10 (a 41% increase from $7.08). So if the warrant holder exercises over $10, I make at least 41% on my shares.
    - company will raise an additional $21.47 million in cash if warrants are exercised

    Added 5K more today.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • Reply to

    Great News!

    by envy_vo Mar 15, 2016 12:14 PM
    factman777 factman777 Mar 15, 2016 12:57 PM Flag

    $70 million cash. Cash for another 3 years. By that time they should be generating revenue from NSS.

    Warrant conversion will raise another $21.5 million

    Currently have about $20 million on the books.
    Units: 4,293,333 x $7.50 = $32,2 million. (gross proceeds of offering are approximately $28 million)
    Warrants: 2,146666 x $10.00 = $21.5 million

    Total = $70 million

    Just the facts,
    -FactMan777 Less

    Sentiment: Strong Buy

  • factman777 by factman777 Mar 15, 2016 10:50 AM Flag

    Warrant conversion will raise another $21.5 million

    Currently have about $20 million on the books.
    Units: 4,293,333 x $7.50 = $32,2 million. (gross proceeds of offering are approximately $28 million)
    Warrants: 2,146666 x $10.00 = $21.5 million

    Total = $70 million

    No more ATM and cashed up for several years.

    What is not to like?

    Management just needs to continue to execute and folks we will have a big winner on our hands.

    Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • factman777 by factman777 Mar 8, 2016 3:35 AM Flag

    For those who missed his tweets about the latest news:

    -PATIENT #5 is now AIS-B at 6-months!!!!!!! HUGE!!!! That’s 3 of 5 so far.

    -NVIV is going to crush the FDA’s objective performance criteria benchmark of 25% in INSPIRE (n=20). They are at 3 of 5 right now (60%).

    -Just the facts,
    -FactMan777

    Sentiment: Strong Buy

  • It is: OFF THE CHARTS.

    3 of 5 patients improving in the AIS scale with a 4th patient (#2) having market bowel and bladder improvement which to many SCI patients is the most important type of recovery.

    So we are 4 of 5 in my book which is 80%.

    Not to mention that we just enrolled patient #6 and now have opened 17 sites.

    Folks, it doesn't get much better than this.

    Can you imagine this stock was at $24 (pre 1:4 reverse split) with a few monkey videos and they had not even started the pilot study. Now we have completed the pilot study which was then rolled into the pivotal study and it is looking more more likely that this pivotal study could be ended in the very near term. With the outstanding working relationship they have developed with the FDA, I bet they will not have to go much past 10 patients if that many.

    I cannot see this stock being under $10 much longer.

    Congratulation to all the longs.

    And that's a fact.
    -FactMan777

    Sentiment: Strong Buy

  • I especially like:

    "and even if the OPC is not met, the FDA may approve a therapy if safety and probable benefit are supported by a comprehensive review of all clinical endpoints and preclinical results."

    Meaning that benefits that patient #2 Jesi has experienced, including bowel and bladder control which is so important to SCI patients, will still be taken into consideration.

    Just the fact,
    -FactMan777

    Sentiment: Strong Buy

NVIV
6.81+0.33(+5.09%)May 24 4:00 PMEDT